Home › New Data from KEYNOTE-028, Mercks Trial Evaluating KEYTRUDA (pembrolizumab) Across a Range of Cancer Types, Presented at 2015 European Cancer Congress
 

Keywords :   


New Data from KEYNOTE-028, Mercks Trial Evaluating KEYTRUDA (pembrolizumab) Across a Range of Cancer Types, Presented at 2015 European Cancer Congress

2015-09-27 13:00:00| Merck.com - Product News

Dateline City: KENILWORTH, N.J. Findings Show Anti-Tumor Activity for KEYTRUDA in Two Gastrointestinal Cancers KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced new findings from the KEYNOTE-028 Phase 1b study, the clinical trial investigating the use of the companys anti-PD-1 therapy, KEYTRUDA (pembrolizumab) in multiple, difficult-to-treat cancers. Data from this trial, to be presented at the European Cancer Congress (ECC) in Vienna, Austria, Sept. Language: English Contact: MerckMedia Contacts:Pamela Eisele, 267-305-3558An Phan, 908-255-6325orInvestor Contacts:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: data range types presented

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
04.05Weekly Recap: Sherwin-Williams, BASF, Abrafati Top This Weeks Stories
03.05'Garden floods show need to work with nature'
03.05Worst-ever job interviews: 'We had to crawl and moo'
03.05Have the wheels come off for Tesla?
03.05BW Converting focuses on time, energy and cost savings at INFOFLEX
03.05Navigator Paper Ups Offer for Accrual
03.05USDA urged to restore NASS surveys
03.05Dilo Hosts Open House
More »